Table 1 Patient, tumor and treatment characteristics of the curative-intent (M0) and palliative-intent (M1) patient cohort and the entire patient collective and the relationship of pre-treatment OPN levels (split at the median) with clinicopathological patient factors (p-value compares pre-treatment OPN levels higher and lower than the median (830.3 ng/ml) and refers to the entire patient collective (n=69)
All patients (n=69) | M0 patients (n=55) | M1 patients (n=14) | Pre-treatment OPN ≤ 830.3 ng/ml | Pre-treatment OPN > 830.3 ng/ml | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | No. | % | No | % | No | % | No | % | No | % | P | |
Age | mean years | 63.1 | 63.4 | 62 | 60.9 | 65.8 | .02 | |||||
Sex | male | 61 | (88) | 47 | (86) | 14 | (100) | 30 | (49) | 31 | (51) | .48 |
female | 8 | (12) | 8 | (14) | 0 | (0) | 5 | (63) | 3 | (37) | ||
Hemoglobin | mean g/dl | 12.1 | 12.1 | 12.1 | 12.5 | 9.3 | .04 | |||||
FeV11 | mean % | 69 | 69 | 65 | 78.1 | 61 | .002 | |||||
weight loss | yes | 22 | (32) | 12 | (22) | 10 | (71) | 7 | (33) | 15 | (67) | .01 |
no | 47 | (68) | 43 | (78) | 4 | (29) | 28 | (64) | 16 | (36) | ||
Histology | SCC 2 | 33 | (48) | 28 | (51) | 5 | (36) | 14 | (42) | 19 | (58) | .33 |
Adeno | 29 | (42) | 24 | (44) | 5 | (36) | 11 | (38) | 18 | (62) | ||
NOS 3 | 7 | (10) | 3 | (5) | 4 | (28) | 3 | (43) | 4 | (57) | ||
Differentiation | well-moderate | 22 | (31) | 20 | (36) | 2 | (14) | 14 | (64) | 8 | (36) | .05 |
poor | 30 | (44) | 25 | (46) | 5 | (36) | 16 | (53) | 14 | (47) | ||
undifferentiated | 17 | (25) | 10 | (18) | 7 | (50) | 5 | (29) | 12 | (71) | ||
UICC stage | I-II | 3 | (4) | 3 | (5) | 0 | (0) | 3 | (100) | 0 | (0) | .33 |
III | 52 | (76) | 52 | (95) | 0 | (0) | 27 | (52) | 25 | (48) | ||
IV | 14 | (20) | 0 | (0) | 14 | (100) | 5 | (36) | 9 | (64) | ||
T stage | 1-2 | 25 | (36) | 20 | (36) | 5 | (36) | 17 | (68) | 8 | (32) | .03 |
3-4 | 44 | (64) | 35 | (64) | 9 | (64) | 18 | (41) | 26 | (59) | ||
N-stage | 0-1 | 10 | (14) | 8 | (14) | 2 | (14) | 4 | (44) | 5 | (66) | .5 |
2-3 | 59 | (86) | 47 | (86) | 12 | (86) | 30 | (51) | 29 | (49) | ||
M stage | 0 | 55 | (80) | 55 | (100) | 0 | (0) | 35 | (64) | 20 | (36) | .03 |
1 | 14 | (20) | 0 | (0) | 14 | (100) | 5 | (36) | 9 | (64) | ||
Mean GTV4 | ml | 200.3 | 219.9 | 117.4 | 176.8 | 261.6 | .02 | |||||
not available | 0 | (0) | 1 | (7) | ||||||||
Radiotherapy | 25 | (36) | 13 | (24) | 12 | (86) | ‡ | |||||
Radio chemotherapy | 44 | (64) | 42 | (76) | 2 | (14) | ||||||
Mean total dose | Gy | 57.9 | 62.9 | 38.2 | ‡ | |||||||
Mean single dose | Gy | 2.2 | 2 | 2.9 | ||||||||
Mean follow-up | months | ‡ | ||||||||||
all patients | 14.6 | 16.7 | 6.5 | |||||||||
living patients | 34.9 | 34.3 | 4.16 | |||||||||